|Bid||98.88 x 1000|
|Ask||99.24 x 800|
|Day's Range||96.81 - 99.45|
|52 Week Range||90.64 - 118.50|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||31.81|
|Earnings Date||May 2, 2019|
|Forward Dividend & Yield||1.48 (1.42%)|
|1y Target Est||107.57|
ResMed today announced it plans to release financial and operational results for the third quarter of fiscal year 2019 on Thursday, May 2, 2019, after the New York Stock Exchange closes.
Resmed's (RMD) Brightree ReSupply is a scalable and automated solution that comprises live-agent inbound and outbound calls for more private interaction with patients and email reminder capabilities.
Now offers “tube-up” design options for nasal and nasal pillows mask wearers, providing even more flexibility and choice to help users sleep better in any position
The Analytics arm, launched by ResMed (RMD) unit Brightree, provides workflow insights and facilitates KPI tracking plus peer benchmarking without the users having to amass the data themselves.
We expect ResMed's (RMD) new product menu and strategies to gain traction from the sleep-disordered breathing market and further drive its near-term performance.
HMEs can now see workflow insights, KPI tracking, and peer benchmarking on one auto-produced dashboard to enhance business decision-making
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Dividends can be underrated but they form a large part of investment returns, playing an important role in compounding return...
A difficult macroeconomic environment and market challenges made the fiscal second quarter the toughest since the formation of Walgreens Boots Alliance (WBA).
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
ResMed (RMD) claims ReSupply solution to improve patient response through growth in the long-term therapy adherence of those suffering sleep apnea.
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Brand-agnostic solution helps HMEs provide timely PAP replacement supplies to sleep apnea patients, increases long-term adherence and improves satisfaction
ResMed (RMD) (RMD.AX) today announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to respiratory care and out-of-hospital software. Additional information regarding the investor meeting, including the specific time and webcast link for the presentations, will be made available approximately one week prior to the event and may be accessed by visiting http://investor.resmed.com. Presentations at the investor meeting will be transmitted by a live webcast, which may be accessed by visiting http://investor.resmed.com.
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll show how you can use ResMed Inc.'s (NYSE:RMD) P/E ratio toRead More...
ResMed Inc NYSE:RMDView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for RMD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold RMD had net inflows of $5.37 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
ResMed's (RMD) Brightree suite upgrade will help uplift business operations by easily meeting compliance needs and offering the best quality patient care.
ResMed (NYSE: RMD, ASX: RMD), a global leader in cloud-connected sleep and respiratory care devices in more than 120 countries, today announced that is has completed the acquisition of HB Healthcare (HBH) to help millions of South Koreans living with sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. HBH, a fast-growing privately owned South Korean home medical equipment provider, serves both reimbursed and cash-pay customers of sleep and respiratory care devices.
- Home infusion therapy providers and HME pharmacies benefit from feature-rich functionality within a single software solution for all clinical, billing and reporting needs
The deal between ResMed's (RMD) MatrixCare and PharMerica covers NCPDP (National Council for Prescription Drug Programs) Bidirectional ePrescribing with all MatrixCare customer facilities.
NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BLOOMINGTON, Minn., Feb. 27, 2019 -- MatrixCare announced today that it has entered into a National Pharmacy Integration and Electronic Medication Administration Record (eMAR).